Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot to stop RSV: landmark trial for indigenous kids

NCT ID NCT07578298

Not yet recruiting Prevention Sponsor: Menzies School of Health Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single dose of nirsevimab, an antibody that targets RSV, can prevent respiratory infections in Aboriginal and Torres Strait Islander children aged 6 months. Around 1,000 children will be randomly assigned to receive either the antibody or standard care. The goal is to see if the shot reduces RSV infections and hospital visits over the next year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nirsevimab (a monoclonal antibody)
What this could lead to
If successful, this could provide a safe and effective way to prevent severe RSV infections in high-risk young children, reducing hospitalisations and health costs.
What could go wrong
This is a single-dose study in a specific population, and results may not apply broadly. The trial is not yet recruiting, and the antibody's long-term effectiveness beyond 12 months is unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY INFECTION VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

viral respiratory tract infection respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY INFECTION VIRUS RESPIRATORY SYNCYTIAL VIRUS (RSV)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Menzies School of Health Research

    Darwin, Northern Territory, 0810, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.